Skip to main content

 Related scientific articles (all)

Immune evasion before tumour invasion in early lung squamous carcinogenesis.

Authors : Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G, Buttard B, Rothé F, Willard-Gallo K, Haller A, Ninane V, Burny A, Sculier JP, Spira A, Galon J
Year : 2019
Journal : Nature
Volume : 571
Pages : 570-575

MicroRNA profiling and identification of let-7a as a target to prevent chemotherapy-induced primordial follicles apoptosis in mouse ovaries.

Authors : Alexandri C, Stamatopoulos B, Rothé F, Bareche Y, Devos M, Demeestere I
Year : 2019
Journal : Sci Rep
Volume : 9
Pages : 9636

Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.

Authors : Matikas A, Zerdes I, Lövrot J, Richard F, Sotiriou C, Bergh J, Valachis A, Foukakis T
Year : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 5717-5726

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.

Authors : Brandão M, Reyal F, Hamy AS, Piccart-Gebhart M
Year : 2019
Journal : ESMO Open
Volume : 4
Pages : e000515

SET<sub>ER/PR</sub>: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer.

Authors : Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Gould R, Zhang Y, King TA, Viale A, Andrade V, Giri D, Salgado R, Laios I, Sotiriou C, Marginean EC, Kwiatkowski DN, Layman RM, Booser D, Hatzis C, Vicente Valero V, Fraser Symmans W
Year : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 16

Denosumab in early-stage breast cancer.

Authors : Brandão M, Debiasi M, de Azambuja E
Year : 2019
Journal : Lancet Oncol
Volume : 20
Pages : e234-e235

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.

Authors : Kirschbrown WP, Kågedal M, Wang B, Lindbom L, Knott A, Mack R, Monemi S, Nijem I, Girish S, Freeman C, Fumagalli D, McConnell R, Jerusalem G, Twelves C, Baselga J, Von Minckwitz G, Bines J, Garg A
Year : 2019
Journal : Cancer Chemother Pharmacol
Volume : 83
Pages : 1147-1158

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.

Authors : Rothé F, Maetens M, Rouas G, Paesmans M, Van den Eynde M, Van Laethem JL, Vergauwe P, Deboever G, Bareche Y, Vandeputte C, Ignatiadis M, Hendlisz A
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 304

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.

Authors : Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C
Year : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 69-77

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer.

Authors : Loi S, Michiels S, Baselga J, Bartlett JMS, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Michael Dixon J, Piccart-Gebhart M, Sotiriou C
Year : 2019
Journal : PLoS One
Volume : 14
Pages : e0216175

Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor.

Authors : Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, DHondt L, Janssens J, Carrasco J, Marechal R, Gomez Galdon M, Heimann P, Paesmans M, Flamen P, Hendlisz A
Year : 2018
Journal : Oncotarget
Volume : 9
Pages : 17756-17769

Breast cancer and pregnancy-related issues.

Authors : Lambertini M, Nguyen B, Viglietti G, Martel S, de Azambuja E
Year : 2018
Journal : Belgian J Medical Oncology
Volume : 11(1)
Pages : 9-14

Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.

Authors : Desmedt C, Demicheli R, Fornili M, Bachir I, Duca M, Viglietti G, Berlière M, Piccart-Gebhart M, Sotiriou C, Sosnowski M, Forget P, Biganzoli E
Year : 2018
Journal : J Natl Cancer Inst
Volume : 110(10)
Pages : 1115-1122

PUBLISHED ERRATUM (2016): PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Authors : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Year : 2018
Journal : Ann Oncol
Volume : 29
Pages : 2151

erratum :Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Authors : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Year : 2018
Journal : Ann Oncol
Volume : 29
Pages : 2152

18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.

Authors : de Cremoux P, Biard L, Poirot B, Bertheau P, Teixeira L, Lehmann-Che J, Bouhidel FA, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, Groheux D
Year : 2018
Journal : Oncotarget
Volume : 9
Pages : 16343-16353

Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.

Authors : Groheux D, Biard L, Lehmann-Che J, Teixeira L, Bouhidel FA, Poirot B, Bertheau P, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, de Cremoux P
Year : 2018
Journal : Eur J Nucl Med Mol Imaging
Volume : 45(8)
Pages : 1279-1288

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Authors : Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, dHollander K, Pantel K
Year : 2018
Journal : J Natl Cancer Inst
Volume : 110(6)
Pages : 560-567

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

Authors : Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, OToole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA Jr, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S
Year : 2018
Journal : J Clin Oncol
Volume : 36(10)
Pages : 981-990

Immuno-oncology-101: overview of major concepts and translational perspectives.

Authors : Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, Routy B, Sotiriou C, Stagg J, Buisseret L
Year : 2018
Journal : Semin Cancer Biol
Volume : 52
Pages : 1-11